Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Progyny ( (PGNY) ) has shared an update.
Progyny reported fourth-quarter 2025 revenue of $318.4 million, up 6.7% year over year, and full-year 2025 revenue of $1.29 billion, up 10%, driven by growth in clients and covered lives despite the loss of a large client under a transition-of-care agreement. Excluding that client, revenue rose 21% in the quarter and 20% for the year, while gross margin expanded, net income improved modestly to $58.5 million, and record operating cash flow of $210.2 million supported share repurchases of about 6.5 million shares and reinforced its position as a growing player in fertility and family-building benefits.
The company’s fourth-quarter 2025 gross profit increased 21% to $76.9 million, with gross margin rising to 24.1% on efficiencies in care management, and full-year gross profit climbed to $304.5 million with a 23.6% margin. Adjusted EBITDA rose to $51.4 million in the quarter and $222.1 million for the year, with stable margins, as Progyny invested in platform expansion and integration of acquisitions while issuing 2026 guidance that points to a tenth consecutive year of revenue growth and continued expansion among large employers and into the fully insured segment.
The most recent analyst rating on (PGNY) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Progyny stock, see the PGNY Stock Forecast page.
Spark’s Take on PGNY Stock
According to Spark, TipRanks’ AI Analyst, PGNY is a Outperform.
Progyny’s strong financial performance and positive earnings call sentiment are the most significant factors driving the score. The technical analysis supports a positive outlook, although the high valuation presents a potential risk. Overall, the company is well-positioned for growth, with strategic initiatives and strong client retention contributing to a favorable outlook.
To see Spark’s full report on PGNY stock, click here.
More about Progyny
Progyny, Inc. is a Nasdaq-listed provider of women’s health and family-building solutions, offering fertility and pharmacy benefit services primarily to large self-insured employers in the U.S. and internationally. The company focuses on comprehensive, outcomes-driven benefit programs and is expanding into the fully insured market while growing its global footprint.
Average Trading Volume: 1,388,447
Technical Sentiment Signal: Sell
Current Market Cap: $1.79B
Find detailed analytics on PGNY stock on TipRanks’ Stock Analysis page.